Plain-English translation of NCT06879704 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether four different imaging scans—ultrasound, mammography, MRI, and PET-CT—can predict how well a patient will respond to chemotherapy combined with pembrolizumab before surgery for triple-negative breast cancer. Doctors want to know if these imaging tests taken before, during, and after treatment can help identify which patients are responding well and which may need a different approach.
When patients receive chemotherapy combined with immunotherapy before surgery, some respond very well while others don't respond at all. This trial is trying to solve the problem of not knowing early enough which patients are benefiting from the medication so that treatment plans can be adjusted sooner if needed.
You likely qualify if…
You likely don't qualify if…
You would have four imaging scans—MRI, PET-CT, ultrasound, and mammography with angiography—performed at specific time points: before your chemotherapy and immunotherapy treatment begins, and before your surgery. These scans help doctors track how your tumor is responding to the medication. You would also continue with your regular cancer treatment plan as recommended by your doctor.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
France